Abstract:Parkinson's disease (PD) is among the most prevalent neurodegenerative disorders, affecting over 10 million people worldwide. The protein encoded by the SNCA gene, alpha‐synuclein (ASYN), is the major component of Lewy body (LB) aggregates, a histopathological hallmark of PD. Mutations and posttranslational modifications (PTMs) in ASYN are known to influence protein aggregation and LB formation, possibly playing a crucial role in PD pathogenesis. In this work, we applied computational methods to characterize the effects of missense mutations and PTMs on the structure and function of ASYN. Missense mutations in ASYN were compiled from the literature/databases and underwent a comprehensive predictive analysis. Phosphorylation and SUMOylation sites of ASYN were retrieved from databases and predicted by algorithms. ConSurf was used to estimate the evolutionary conservation of ASYN amino acids. Molecular dynamics (MD) simulations of ASYN wild‐type and variants A30G, A30P, A53T, and G51D were performed using the GROMACS package. Seventy‐seven missense mutations in ASYN were compiled. Although most mutations were not predicted to affect ASYN stability, aggregation propensity, amyloid formation, and chaperone binding, the analyzed mutations received relatively high rates of deleterious predictions and predominantly occurred at evolutionarily conserved sites within the protein. Moreover, our predictive analyses suggested that the following mutations may be possibly harmful to ASYN and, consequently, potential targets for future investigation: K6N, T22I, K34E, G36R, G36S, V37F, L38P, G41D, and K102E. The MD analyses pointed to remarkable flexibility and essential dynamics alterations at nearly all domains of the studied variants, which could lead to impaired contact between NAC and the C‐terminal domain triggering protein aggregation. These alterations may have functional implications for ASYN and provide important insight into the molecular mechanism of PD, supporting the design of future biomedical research and improvements in existing therapies for the disease.

Comparative Studies in the A30P and A53T α-Synuclein C. elegans Strains to Investigate the Molecular Origins of Parkinson's Disease

In silico analysis of alpha‐synuclein protein variants and posttranslational modifications related to Parkinson's disease

Non-Motor Parkinsonian Pathology In Aging A53t Alpha-Synuclein Mice Is Associated With Progressive Synucleinopathy And Altered Enzymatic Function

Genomic DNA Levels of Mutant Alpha-Synuclein Correlate with Non-Motor Symptoms in an A53T Parkinson's Disease Mouse Model

Novel C. elegans models of Lewy body disease reveal pathological protein interactions and widespread miRNA dysregulation

3,4‐Dihydroxyphenylethanol and 3,4‐dihydroxyphenylacetic acid affect the aggregation process of E46K variant of α‐synuclein at different extent: Insights into the interplay between protein dynamics and catechol effect

Models of α-synuclein aggregation in Parkinson’s disease

Motor deficits and brain pathology in the Parkinson's disease mouse model hA53Ttg

Generation of G51D and 3D mice reveals decreased α-synuclein tetramer-monomer ratios promote Parkinson’s disease phenotypes

Endoplasmic Reticulum Stress and Mitochondrial Cell Death Pathways Mediate A53T Mutant Alpha-Synuclein-induced Toxicity.

Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease

Templating of Monomeric Alpha-Synuclein Induces Inflammation and SNpc Dopamine Neuron Death in a Genetic Mouse Model of Synucleinopathy.

Exploring α-synuclein Interaction Partners and their Potential Clinical Implications for Parkinson's Disease

Neuropathology in Mice Expressing Human Alpha-Synuclein.

α-Synuclein Aggregates in the Nigro-Striatal Dopaminergic Pathway Impair Fine Movement: Partial Reversal by the Adenosine A2A Receptor Antagonist

Bradykinesia and postural instability in a model of prodromal Synucleinopathy with α-Synuclein aggregation in the gigantocellular nuclei

Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies

The A53T Mutation in α-Synuclein Enhances Proinflammatory Activation in Human Microglia Upon Inflammatory Stimulus

Motor and Nonmotor Features of p.A53T Alpha-Synuclein PD vs idiopathic PD: Longitudinal Data from the PPMI Study.

β-synuclein regulates the phase transitions and amyloid conversion of α-synuclein

Α‐synuclein Stimulation of Monoamine Oxidase‐b and Legumain Protease Mediates the Pathology of Parkinson's Disease